ES019 / Elpiscience, Astellas - LARVOL DELTA

Elpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage Engager (Businesswire) - "Elpiscience…and Astellas Pharma Inc…today announced a research collaboration and license agreement for novel bi-specific macrophage engagers, ES019 and another program. The two companies will collaboratively conduct early-stage research for these two programs. Elpiscience will also grant Astellas the right to add up to two additional programs to be included in the collaboration. If Astellas exercises its option, Elpiscience will grant Astellas the exclusive right to further research, develop, manufacture and commercialize the products for each program….Elpiscience will receive up to US $37 million, including the upfront payment and license option fees."

Licensing / partnership • Oncology • Solid Tumor

ES-019, a PD-L1/SIRPα bispecific macrophage engager, shows antitumor efficacy in vivo (Bioworld) - "Researchers from Elpiscience Biopharma Ltd. have reported the construction of a PD-L1/SIRPα bispecific macrophage engager (BiME), ES-019. A panel of anti-PD-L1/SIRPα antibodies based on single domain antibody was generated, with the candidates containing different orientations, ratios and IgG isotypes of anti-PD-L1 arm and anti-SIRPα arm."

Preclinical • Oncology

Dual Targeting of Innate and Adaptive Immune Checkpoints with a PD-L1/SIRPα Bispecific Macrophage Engager to Promote Anti-tumor Activity (SITC 2022) - "In summary, we demonstrated that ES019 exhibited super anti-cancer effects, evidenced by potent phagocytosis in vitro and almost complete tumor regression in vivo . Conclusions Using our bispecific macrophage engager (BiME) platform, we have developed a PD-L1/SIRPα bispecific antibody that is capable of activating both macrophages and T cells to kill cancer cells with the potential to overcome the limitations of traditional anti-PD1 therapies."

Oncology • CD47 • SIRPA

Elpiscience Announces Studies Presented at SITC 2022 Annual Meeting (Businesswire) - "Elpiscience Biopharmaceuticals...presented positive studies for its innovative immunotherapeutic molecules at the SITC 2022 Annual Meeting....Abstract No.: 1211...Highlights: (i) ES019 activates T cells without induction of phagocytosis of T cells; (ii) ES019 shows favorable PK in mouse model; (iii) ES019 demonstrates single agent anti-tumor efficacy in animal model."

Preclinical • Oncology

Elpiscience Announces Five Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting (Businesswire) - "Elpiscience Biopharmaceuticals...announced it will have five poster presentations at the SITC 2022 Annual Meeting being held in Boston, Massachusetts from November 8-12. The posters will highlight studies on five innovative molecules including anti-SIRPα monoclonal antibody ES004, anti-LAG3 monoclonal antibody ES005, anti-LILRB2 monoclonal antibody ES009, anti-SIGLEC15 antibody ES012, and PD-L1/SIRPα bispecific macrophage engager ES019."

Preclinical • Oncology